Pi3k-mtor In Cancer And Cancer Therapy by Nandini Dey

Pi3k-mtor In Cancer And Cancer Therapy

byNandini DeyEditorPradip De, Brian Leyland-Jones

Paperback | May 31, 2018

Pricing and Purchase Info

$295.81 online 
$312.50 list price save 5%
Earn 1,479 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway''s involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance.   Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.
Nandini Dey, M.S., Ph.D., is a Senior Scientist Head of Cancer Biology, Avera Cancer Institute Center for Precision Oncology. She is also Assistant Professor of the Department of Internal Medicine at The University of South Dakota Sanford School of Medicine. Dey has more than 20 years of experience in translational research and has aut...
Title:Pi3k-mtor In Cancer And Cancer TherapyFormat:PaperbackProduct dimensions:294 pages, 9.25 X 6.1 X 0 inShipping dimensions:294 pages, 9.25 X 6.1 X 0 inPublished:May 31, 2018Publisher:Humana PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3319817043

ISBN - 13:9783319817040

Appropriate for ages: All ages

Look for similar items by category:

Table of Contents

PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics.- Part 1: PI3K-mTOR Pathway in Cancers.- The mTOR Complexes in Cancer Cell Metabolism.- PI3K-AKT-mTOR Pathway Co-operates with the DNA Damage Repair Pathway: Carcinogenesis in Triple Negative Breast Cancers and Beyond.- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures.- Resistance to PI3K Pathway Inhibition.- Part 2: PI3K-mTOR Pathway in Cancer Medicine.- Combination Therapies Targeting the PI3K/AKT/mTOR Pathways.- Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma.- HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies.- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities.